A nicotinic acid (Nicotinic acid)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspinjection
Composition:

Per 1 ml:

Active substance: nicotinic acid - 10.0 mg.

Excipients: sodium hydrogen carbonate - 7.0 mg, water for injection - up to 1 ml.
Description:Pcolorless liquid.
Pharmacotherapeutic group:Vitamin
ATX: & nbsp
  • A nicotinic acid
    • Pharmacodynamics:

    Nicotinic acid is a specific anti-pelagic agent. It has a pronounced short vasodilating effect, improves carbohydrate and nitrogen metabolism, improves microcirculation.

    In organism a nicotinic acid turns into nicotinamide, which binds to the coenzymes of codohydrase I and codohydrase II (NAD and NADO), which carry hydrogen, participates in the metabolism of proteins, amino acids, purines, tissue respiration, glycogenolysis, and synthetic processes.

    Replenishes vitamin PP deficiency (vitamin B3).

    Has vasodilating effect at the level of small vessels (including the brain), improves microcirculation, has a weak anticoagulant effect (increases fibriolytic activity of the blood).

    Pharmacokinetics:

    When parenteral administration is rapidly distributed in the tissues of the body. It accumulates mainly in the liver, as well as in adipose tissue and in the kidneys.

    In the liver a nicotinic acid is converted into an amine that is embedded in nicotinamide adenine dinucleotide (NAD), which is a prosthetic group of enzymes that carry hydrogen and carry out oxidation-reduction processes. The main metabolites are Nmethyl-2-pyridone-3-carboxamide and Nmethyl-2-pyridone-5-carboxamide, which do not possess pharmacological activity.

    It can be synthesized in the intestine by a bacterial flora from the tryptophan that came with food (60 mg of tryptophan produces 1 mg of nicotinic acid) with the participation of pyridoxine (vitamin B6) and riboflavin (vitamin B2).

    The elimination half-life is 45 minutes.

    It is excreted from the body by the kidneys in unmodified form and in the form of metabolites, when taking high doses - mostly unchanged. Kidney clearance depends on the level of nicotinic acid in the blood plasma and can decrease with a high concentration of it in the plasma.

    Indications:

    - Hypovitaminosis PP, avitaminosis PP (pellagra);

    - In the combination therapy:

    • with ischemic stroke;
    • with obliterating diseases of the vessels of the extremities (obliterating endarteritis, Raynaud's syndrome);
    • with neuritis of the facial nerve;
    • with diabetes mellitus, including its complications (diabetic polyneuropathy, microangiopathy);

    - Hartnup disease (hereditary disease, accompanied by a violation of the assimilation of certain amino acids, including tryptophan).

    Contraindications:

    Atherosclerosis, hypersensitivity to nicotinic acid, peptic ulcer of the stomach and duodenum (at the stage of exacerbation), gout, hyperuricemia, hepatitis, cirrhosis, decompensated diabetes mellitus.

    Carefully:

    Hemorrhagia, glaucoma, hyperacid gastritis, peptic ulcer of the stomach and duodenum (outside the stage of exacerbation), arterial hypotension, pregnancy, lactation, children's age.

    Pregnancy and lactation:

    Taking into account the injection route of the drug, its side effects, the use during pregnancy strictly according to the doctor's prescription, if the expected effect of therapy for the mother exceeds the potential risk to the fetus.

    If you need to use the drug during lactation, breastfeeding should be discontinued.

    Dosing and Administration:

    With pellagra Assign adults parenterally (intravenously, intramuscularly or subcutaneously) 1 ml of 1% (10 mg) solution 2-3 times a day for 10-15 days.

    With ischemic stroke 10 mg of solution is slowly injected intravenously.

    With other indications - 10 mg 1-2 times a day for 10-15 days.

    Higher doses for adults: single dose - 100 mg, daily - 300 mg.

    Hartnup disease - 40-200 mg per day.

    Side effects:

    From the cardiovascular system: sensation of "tidal" blood to the scalp, hyperemia of the facial skin and upper body, orthostatic hypotension, collapse, sensation of fever, headache. With rapid intravenous administration, a significant reduction in blood pressure, dizziness.

    From the central and peripheral nervous system: paresthesia, dizziness.

    From the digestive system: with prolonged use - fatty degeneration of the liver.

    From the side of metabolism: with long-term use - hyperuricemia, decreased glucose tolerance, asthenia, increased blood levels of aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase.

    Local Reactions: soreness in the injection site with subcutaneous and intramuscular injections.

    Other: allergic reactions (skin rash, skin, stridorous respiration, urticaria).

    Overdose:

    High doses of nicotinic acid can cause a temporary rush of blood to the head and upper body, itching, and gastrointestinal upsets.

    Treatment: withdrawal of the drug, symptomatic therapy. There is no specific antidote.

    Interaction:

    When combined with the drugs, sulfonylureas can increase blood glucose levels.

    When administered with lovastatin increases the risk of myopathy.

    Care should be taken when combining with antihypertensive drugs, anticoagulants and ascorbic acid.

    Reduces the toxicity of neomycin and prevents the induced decrease in the concentration of high-density cholesterol and lipoproteins.

    Special instructions:

    To prevent complications from the liver it is recommended to include in the diet products rich in methionine (cottage cheese), or use methionine, lipoic acid and other lipotropic drugs.

    Effect on the ability to drive transp. cf. and fur:

    Data on the impact on the ability to drive vehicles or work with mechanisms are not available. However, some unwanted reactions (orthostatic hypotension, collapse, dizziness (cm.section "Side effect")) can have a negative impact on the ability to drive vehicles or work with other mechanisms. Patients who report these adverse reactions are advised not to drive vehicles or work with other mechanisms until these symptoms disappear completely.

    Form release / dosage:

    Solution for injection, 10 mg / ml.

    Packaging:

    1 ml of the drug in ampoules according to ISO 9187 from colorless glass I of the hydrolytic class.

    5 ampoules per contour cell packaging made of polyvinyl chloride film.

    1 or 2 contour squares, together with instructions for use, are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004129
    Date of registration:08.02.2017
    Expiration Date:08.02.2022
    The owner of the registration certificate:FARMSTANDART-UFAVITA, JSC FARMSTANDART-UFAVITA, JSC Russia
    Manufacturer: & nbsp
    Representation: & nbspPHARMSTANDART-Ufa-VITA, JSCPHARMSTANDART-Ufa-VITA, JSC
    Information update date: & nbsp05.03.2017
    Illustrated instructions
      Instructions
      Up